Amundi Grows Holdings in IQVIA Holdings Inc. $IQV

Amundi grew its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 957,792 shares of the medical research company's stock after acquiring an additional 88,789 shares during the period. Amundi owned about 0.58% of IQVIA worth $185,065,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of IQV. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Compass Financial Management LLC purchased a new stake in shares of IQVIA during the second quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $27,000. CrossGen Wealth LLC purchased a new position in IQVIA in the 4th quarter valued at about $28,000. Finally, Financial Freedom LLC acquired a new stake in IQVIA in the 1st quarter worth about $25,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 3.1%

NYSE IQV opened at $259.49 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.71 billion, a P/E ratio of 32.19, a PEG ratio of 2.29 and a beta of 1.18. The firm's 50-day moving average is $233.34 and its two-hundred day moving average is $194.19. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same period last year, the business earned $2.81 earnings per share. The business's revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

Insider Activity at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company's stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 over the last ninety days. Company insiders own 1.70% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. TD Cowen raised their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Saturday, August 29th. BMO Capital Markets increased their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. Finally, Barclays reissued an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $243.62.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.